studies, as concluded in the ADA-EASD 2022 consensus
report.144 In addition, in post hoc analyses, these drugs
had beneÔ¨Åcial cardiovascular and renal effects in people
with peripheral artery disease.145 However, individuals
with foot ulcers were frequently excluded in SGLT-2 inhibitor trials and there is a second caveat to be considered.
Diabetes related ketoacidosis is a rare but serious side effect of SGLT-